Stoke Therapeutics, Inc.
corporate_fare Company Profile
Stoke Therapeutics, Inc. (NASDAQ:STOK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for STOK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for STOK spans 10-Q, 144, 424B5, 8-K.
Recent high-impact activity:
- Stoke 10-Q: $358.8M Cash Into Early 2028, Q3 Loss Widens to $73.6M
- Stoke Posts $73.6M Q3 Loss as Dravet Phase 3 Nears Readout, Cash Runs to Early 2028
- Former Director Kaye Notices Sale of 1.5M Shares (~$38M) After Option Exercise
- FDA Aligns on Zorevunersen NDA Plan, Stoke Eyes 2028 Launch
- Stoke's Zorevunersen Shows Durable Seizure and Cognitive Gains in 4-Year Dravet Data
Financial Snapshot
Short Interest & Short Volume
6.75 days to coverFINRA reported short interest of 10,722,415 shares in STOK as of the October 30, 2026 settlement, a 4.5% increase from the prior period — about 6.8 days to cover at its recent average daily volume. On November 20, 2026, 72.6% of STOK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for STOK, detected from its recent SEC filings · based on capital-structure filings through 2026-08-03.
ATM Program Upsized to $200M · Prior Sales Total $146.4M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →